A5013589035- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Inhalation and Respiratory Drug Delivery
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Radiopharmaceutical Chemistry and Applications
- Viral Infections and Immunology Research
- Gold and Silver Nanoparticles Synthesis and Applications
- Ubiquitin and proteasome pathways
- Cancer, Lipids, and Metabolism
- RNA modifications and cancer
- Protein Degradation and Inhibitors
- Asthma and respiratory diseases
- Advanced Proteomics Techniques and Applications
- Electron Spin Resonance Studies
- Animal Virus Infections Studies
- PI3K/AKT/mTOR signaling in cancer
- Chemokine receptors and signaling
- Nanoparticle-Based Drug Delivery
- SARS-CoV-2 and COVID-19 Research
- Cancer-related gene regulation
Tuskegee University
2015-2023
Center for Cancer Research
2018-2023
Sohag University
2023
Baylor Scott & White Health
2013
Hospice Austin
2013
The University of Texas at Tyler
2013
Solid tumors elicit a detectable immune response including the infiltration of tumor-associated macrophages (TAMs). Unfortunately, this is co-opted into contributing toward tumor growth instead preventing its progression. We seek to reestablish an antitumor by selectively targeting surface receptors and endogenous signaling processes macrophage subtypes driving cancer RP-182 synthetic 10-mer amphipathic analog host defense peptides that induces conformational switch mannose receptor CD206...
Activated M2-polarized macrophages are drivers of pulmonary fibrosis in several clinical scenarios, including Idiopathic Pulmonary Fibrosis (IPF). In this study, we investigated the effects targeting CD206 receptor M2-like with a novel synthetic analogue naturally occurring Host Defense Peptide (HDP), RP-832c, to decrease profibrotic cytokines. RP-832c selectively binds on bone marrow-derived (BMDM) vitro, resulting time-dependent expression and transient increase M1-macrophage marker TNF-α....
Abstract: As an alternative therapeutic treatment to reduce or eliminate the current side effects associated with advanced prostate cancer (PCa) chemotherapy, a multifunctional double-receptor-targeting iron oxide nanoparticles (IONPs) (luteinizing hormone-releasing hormone receptor [LHRH-R] peptide- and urokinase-type plasminogen activator [uPAR] peptide-targeted nanoparticles, LHRH-AE105-IONPs) drug delivery system was developed. Two tumor-targeting peptides guided this nanoscale system....
Activated M2 polarized macrophages are drivers of pulmonary fibrosis in several clinical scenarios such as Acute Respiratory Disease Syndrome (ARDS) and Idiopathic Pulmonary Fibrosis (IPF), through the production inflammatory fibrosis-inducing cytokines. In this study, we investigated effect targeting CD206 receptor with a novel fragment Host Defense Peptide (HDP), RP-832c to decrease cytokines that cause fibrosis. selectively binds on bone marrow derived (BMDM) vitro , resulting...
The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. Here we demonstrate that recurrent mutations have differential effects on endocrine therapy responsiveness, metastasis, TKI therapeutic sensitivity. prevalence prognostic significance may also depend whether the mutant has arisen in context of lobular versus ductal histology. most highly...
Tumor-associated macrophages (TAMs) are large phagocytic cells that play numerous roles in cancer biology and an important component of the relationship between immune system response tumor progression. The peptide, RP832c, targets Mannose Receptor (CD206) expressed on M2-like is cross-reactive to both human murine CD206. Additionally, it exhibits therapeutic properties through its ability shift population TAMs from (protumor) toward M1-like phenotype (antitumor) has demonstrated promise...
Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed solid including ovarian cancer. Consequently, interest is mounting in alternative non-peptide based drugs targeting proteasome's 19S regulatory particle subunit, its ubiquitin receptor RPN13. RA183 RA375 are more potent analogs of prototypic inhibitor RPN13 (iRPN13) called RA190, they promise for treatment Here we demonstrate that rendering these...
African American (AA) women with breast cancer are more likely to have higher inflammation and a stronger overall immune response, which correlate poorer outcomes. In this report, we applied the nanostring panel identify differences in inflammatory gene expression by race. We observed of multiple cytokines AA patients compared EA patients, high CD47, TGFB1, NFKB1 associated transcriptional repressor Kaiso. To investigate mechanism pattern, that Kaiso depletion results decreased its ligand...
<ns5:p><ns5:bold>Background: </ns5:bold>Over 60% of the United States population is infected with herpes simplex virus 1 (HSV-1). Current HSV-1 treatment regimens exert their antiviral effects through a common mechanism action and suffer from high dosing frequencies, which may contribute to patient noncompliance subsequent development resistance. Although primarily known for functions in maintaining homeostatic control arterial blood osmotic pressures, components Renin-Angiotensin...
Abstract Background.Targeting HER2 gene amplification is one of the great achievements in oncology resulting use a wide array anti-HER2 agents clinic. Unfortunately, 20% patients still relapse with secondary organ metastasis and are currently incurable. While only 1.6% primary non-HER2-amplified ER+ breast cancers harbor mutations, 6-10% all metastatic suggesting their causal role contributing to metastasis. The clinical value activating mutations being tested pan-HER tyrosine kinase...
Background: Prostate cancer (PCa) is higher among African American (AA) than Caucasian Americans (CA). AAs are more frequently diagnosed with PCa worse prognoses CAs. Support of a genetic component to the high incidence and mortality rate in AA men based on epidemiologic studies similar backgrounds. For instance, Ghana Nigeria also have prostate cancer, as do descent Caribbean islands United Kingdom. Multiple reports indicate that aggressiveness result stem cells (CSC). Furthermore, people...
Abstract Prostate Cancer (PCa) is the second leading cause of cancer-related deaths among men in United States. Due to harsh side effects conventional chemo- and radiotherapies, targeted drug delivery now gaining focus cancer researchers. The key for success any newly developed systems novel design targeting peptides which have high binding affinities differentially over-expressed receptors on surface PCa cells. Two such receptors, can be cell cells are: Gonadotropin Releasing Hormone...
Abstract Purpose: Prostate Cancer (PCa) is the second leading cause of cancer-related deaths among men in United States. Due to harsh side effects conventional chemo- and radio-therapies, targeted drug delivery now gaining focus cancer researchers. The key for success any newly developed systems novel design targeting peptides which have high binding affinities differentially over-expressed receptors on surface PCa cells. Four can be cell cells are: (GnRH), (EGFR), (PSMA), (uPAR). Thus, we...
<div>Abstract<p>The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. Here we demonstrate that recurrent mutations have differential effects on endocrine therapy responsiveness, metastasis, TKI therapeutic sensitivity. The prevalence prognostic significance may also depend whether the mutant has arisen in context of lobular versus...
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer